A Multicentre, Randomised, Double-Blind, Placebo Controlled, Phase II Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable Implants of Afamelanotide (CUV1647) for the Prophylactic Treatment of Pre-Cancerous Skin Lesions of the Head, Forearms and Hands in Immune Compromised, Organ Transplant Patients.

Trial Profile

A Multicentre, Randomised, Double-Blind, Placebo Controlled, Phase II Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable Implants of Afamelanotide (CUV1647) for the Prophylactic Treatment of Pre-Cancerous Skin Lesions of the Head, Forearms and Hands in Immune Compromised, Organ Transplant Patients.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2014

At a glance

  • Drugs Afamelanotide (Primary)
  • Indications Actinic keratosis; Skin cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Clinuvel Pharmaceuticals
  • Most Recent Events

    • 15 Dec 2011 Interim results (blinded data) published in the Media Release.
    • 24 Jan 2011 First results expected in 2011, according to a Clinuvel Pharmaceuticals media release
    • 03 Dec 2010 Planned End Date changed from 1 Dec 2010 to 1 Aug 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top